NOVEMBER 4, 2024
FDA GRANTS R3 VASCULAR IDE APPROVAL FOR ELITE-BTK PIVOTAL TRIAL OF ITS MAGNITUDE® DRUG ELUTING NEXT- GENERATION BIORESORBABLE SCAFFOLD FOR BELOW-THE-KNEE PERIPHERAL ARTERIAL DISEASE
MOUNTAIN VIEW, CA – November 4, 2024 – R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce that the U.S. Food and Drug Administration (FDA) granted investigational device exemption (IDE) approval to initiate its ELITE-BTK pivotal trial of its next-generation drug-eluting bioresorbable scaffold, MAGNITUDE®, for below-the-knee (BTK) PAD. […]
JULY 9, 2024
R3 Vascular Appoints Josh Smale as its Vice President of Global Clinical and Scientific Affairs
MOUNTAIN VIEW, CA – July 9, 2024 – R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce the appointment of Josh Smale as its Vice President of Global Clinical and Scientific Affairs. […]
MAY 9, 2024
R3 Vascular Announces $87 Million in Series B Financing and Appoints Christopher M. Owens as new President and CEO
MOUNTAIN VIEW, CA – May 9, 2024 – R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), announced today the closing of its $87 million Series B financing round. The company also announced that veteran medical device executive Christopher M. Owens will serve as its new President and Chief Executive Officer. Mr. Owens succeeds the founder Kamal Ramzipoor, who will step into the role of Chief Technology Officer (CTO) […]
SEPTEMBER 2, 2021
R3 Vascular Reports the Initiation of Its First-In-Human Clinical Study
MOUNTAIN VIEW, CA – September 2, 2021 (BUSINESS WIRE) – R3 Vascular Inc. today reported the successful initiation of its First-in-Human clinical study evaluating the technical and clinical performance of the R3 Vascular MAGNITUDE® Bioresorbable Sirolimus-Eluting Scaffold (BRS) in patients suffering of Critical Limb Ischemia (CLI) due to occlusive below the knee (BTK) arterial disease […]